Agilent Technologies Inc (A) is Reiterated by Jefferies to Buy, Raises Price Target to $ 51

Agilent Technologies Inc (A) was Reiterated by Jefferies to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 51 from a previous price target of $46 . Jefferies advised their investors in a research report released on May 17, 2016.

On the company’s financial health, Agilent Technologies Inc reported $0.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on May 16, 2016. Analyst had a consensus of $0.39. The company had revenue of $1019.00 million for the quarter, compared to analysts expectations of $983.35 million. The company’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.38 EPS.

Agilent Technologies Inc opened for trading at $42.61 and hit $43.07 on the upside on Monday, eventually ending the session at $42.94, with a gain of 0.75% or 0.32 points. The heightened volatility saw the trading volume jump to 39,79,321 shares. Company has a market cap of $14,074 M.

In a different news, on May 12, 2016, Dominique Grau (Senior Vice President) sold 10,322 shares at $43.00 per share price. According to the SEC, on Apr 4, 2016, Heidi Fields (director) sold 30,000 shares at $39.91 per share price. On Mar 21, 2016, Robert J Herbold (director) sold 8,072 shares at $40.30 per share price, according to the Form-4 filing with the securities and exchange commission.

Agilent Technologies Inc. is engaged in the life sciences diagnostics and applied chemical markets. The Company provides application focused solutions that include instruments software services and consumables for the entire laboratory workflow. The Company has three business segments: the life sciences and applied markets business the diagnostics and genomics business and the Agilent CrossLab business. The Company’s life sciences and applied markets business segment brings together the Company’s analytical laboratory instrumentation and informatics. The Company’s diagnostics and genomics business segment consists of three businesses: the Dako business the genomics business and the nucleic acid solutions business. The Company’s Agilent CrossLab business segment combines its analytical laboratory services and consumables business.

Agilent Technologies Inc

Leave a Reply

Agilent Technologies Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Agilent Technologies Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.